| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 6 May 2025 | 29 Apr 2025 |
| Poly Medicure Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 inter alia to consider and approve The Company has informed the Exchange about the Board Meeting scheduled to be held on 06th May 2025 for the purpose of approving the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March 2025 and also Final Dividend for the Financial Year ended 31st March 2025. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, We are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 06th May, 2025, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020, approved the following businesses: a. Audited Financial Results (Consolidate & Standalone) for the Fourth quarter and financial year ended on 31st March 2025. b. Recommendation of Dividend of Rs. 3.50 (Three and half Rupees) per Equity Shares (70%) of Rs. 5 each for the Financial Year 2024-25, subject to the approval of shareholders. c. Appointment of Mr. Vishal Baid, DIN: 00232727 as an Executive Director on board subject to shareholders approval in ensuing General Meeting. d. Mrs. Mukulika Baid, Non Executive Non Independent Director Step Down from the Directorship of the Company. e. Appointment of Auditor(s) (As per BSE Announcement Dated on 06/05/2025) | ||
| Board Meeting | 3 Feb 2025 | 27 Jan 2025 |
| POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve The Company informed the Exchange about the Board Meeting to be held on 03rd February 2025. Pursuant to the Regulation 30 of SEBI(LODR) Regulations, 2015, Company has informed about the outcome of the Board Meeting held on today i.e. 03rd February, 2025. The Company has informed about the Unaudited Financial Results ( Standalone & Consolidated ) for the Third quarter and nine months ended on 31st December, 2024 (As per BSE Announcement Dated on 03/02/2025) | ||
| Board Meeting | 28 Oct 2024 | 19 Oct 2024 |
| POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve The Company informed the Exchange about the upcoming Board Meeting Scheduled to be held on 28th October 2024 The Company has informed the exchange about the outcome of the Board Meeting held on today i.e. 28th October, 2024. (As Per BSE Announcement dated on 28.10.2024) | ||
| Board Meeting | 22 Jul 2024 | 17 Jul 2024 |
| POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2024 inter alia to consider and approve Dear Sir/Madam Pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that a meeting of the Board of Director of the Company will be held on Monday the 22nd July 2024 inter alia to consider the following: a. To consider and approve the Unaudited Financial Results (Consolidated & Standalone) of the company for the First Quarter ended 30th June 2024. b. To transact any other matter which the Board may deem fit. In continuation of our intimation regarding closure of trading window vide letter dated 29th June 2024 the Trading Window for dealing in securities of the company shall remain closed till 24th July 2024. Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 22nd July, 2024 232-B, 3rd Floor, Okhla Industrial Estate, Phase-III, New Delhi-110020, approved the following businesses: a) Unaudited Financial Results (Consolidate & Standalone) for the first quarter ended on 30th June 2024. b) To Re-appoint and Ratification of Remuneration of M/s. Jai Prakash & Company, Cost Accountants as Cost Auditors of the Company for the Financial Year 2024-25, subject to the approval of the shareholders in the forthcoming Annual General Meeting. c) To appoint Mr. Vimal Bhandari (DIN 0001318), as Non-Executive and Independent Director on the Board of the Company, subject to shareholder approval in upcoming Annual general meeting (As per BSE Announcement Dated on 22/07/2024) | ||
| Board Meeting | 29 Jun 2024 | 25 Jun 2024 |
| POLY MEDICURE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/06/2024 inter alia to consider and approve Pursuant to Regulation 29(1) and 29(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 in continuation with our Board Meeting held on 08th March 2024 in which Board has approved Raising of funds intimation is hereby given that a Meeting of Board of Directors is scheduled to be held on Saturday the 29th June 2024 inter alia to consider and finalize the terms and condition and approve the modes of fund raising. Further in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys code of Conduct for Prevention of Insider Trading the Trading Window for dealings in the Companys securities will be closed till further notice. The Board would also consider convening an extra-ordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of fund raising as required. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we are pleased to inform the Stock Exchange that the Board of Directors at their meeting held today i.e. 29th June, 2024, at 232-B, 3rd Floor, Okhla Industrial Estate, Phase -III, New Delhi- 110020, has considered and approved the proposal for raising of funds through issuance of new securities by way Qualified Institutional Placement (QIP) and seeking approval of the members by way of Special Resolution for the same and in this regard we wish to submit as under :- a) The Board has considered and approved raising of funds to the tune of amount not exceeding INR 1,000 Crore (One Thousand Crore) through new issue of equity shares by way of qualified institutions placement, in accordance with the relevant provisions of applicable law and subject to approval of the Companys shareholders and receipt of applicable regulatory approvals. (As Per BSE Announcement Dated on 29.06.2024) | ||
Here are some of the stocks that may see significant price movement today; Bajaj Auto, Zomato, Nucleus Software, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
